CTSA Program Posters

  • Medical University Of South Carolina

    Rural health disparities are growing, with mortality rates improving more slowly in rural compared to urban areas (1). In 2017, the CDC reported rural disparities in age-adjusted excess mortality across the five leading potentially preventable causes of death: heart disease, cancer, unintentional injury, chronic respiratory disease, and stroke (2). In South Carolina (SC), 36 of 44 counties are

  • Wake Forest University Health Sciences

    Background: According to the National Institutes of Health, translation is defined by NCATS as turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and communities. Translational Science is the field of investigation focused on understanding the scientific and operational principles underlying each step of the translation process. A

  • Radiomics Cluster Poster Image
    University Of Chicago

    The Institute for Translational Medicine (ITM) aims to make research breakthroughs happen and to put those discoveries into the real world to improve health. The ITM is a partnership between the University of Chicago and Rush in collaboration with Advocate Health Care, the Illinois Institute of Technology, Loyola University Chicago, and NorthShore University HealthSystem. The goal of the ITM

  • Trial Innovation Network – Practical Resources to Support Multi-Site Trials in the CTSA Program
    Trial Innovation Network

    The Trial Innovation Network (TIN) is an established partnership with the CTSA Program, the National Center for Advancing Translational Science (NCATS), and other NIH Institutes and Centers. Currently (AUG 2019) the TIN is supporting 212 projects, including 134 active studies that represent 59 therapeutic areas. These projects create opportunities for the CTSA Program Hubs, the Trial Innovation

  • University Of Washington

    Introduction The COVID-19 pandemic has claimed over 220,000 lives in the United States. A promising resource for discovery in COVID-19’s symptom progress is data documented in electronic health record (EHR) systems as part of clinical care. Such data are stored in disparate locations within the EHR, requiring multiple extraction methods. Methods Symptoms were extracted from EHR data for all

  • Ohio State University

    The Ohio State University CCTS is developing a comprehensive support system for researchers to work with existing datasets through data curation and access, financial support for innovative research ideas, and education about practical data issues and challenges.

  • Johns Hopkins University

    BACKGROUND Researchers have had to explore new modes of patient identification and recruitment due to the restrictions and resource limitations caused by the COVID-19 pandemic. Electronic health record (EHR)-based participant identification and recruitment through patient portal messaging offer potential solutions to help researchers meet recruitment goals without the additional risk of in-person

  • Oregon Health and Science University

    An important untapped resource for clinical trial and research recruitment is community-based primary care centers, including rural health clinics, federally-qualified health centers and other community health centers. These centers are where many receive care, often from diverse populations underrepresented in clinical research. Despite this promise, there are notable barriers to conducting

  • CIDD in San Antonio – an Integrated Model for Early Stage Drug Discovery in Academia
    University Of Texas Health Science Center

    The Center for Innovative Drug Discovery (CIDD), a joint-venture between the University of Texas Health at San Antonio (UTHealthSA) and the University of Texas at San Antonio (UTSA), provides core-based services that support biomedical research related to drug discovery. The primary goal of CIDD is to provide a diverse array of technologies and expertise to enable the translation of basic

  • Drug Discovery at UIC
    University Of Illinois At Chicago
    UICentre is a campus-wide small molecule drug discovery initiative at the University of Illinois at Chicago associated with the Center for Clinical and Translational Sciences (CTSA). Using established core instrumentation and with modest annual support, UICentre was conceived to utilize existing resources to leverage the expertise of scientist and clinicians teams across campus in collaborative